THERAPIX BIOSCIENCES LTD Inactive Instrument
Therapix Biosciences Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
TRPX
IL0010951403
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - ILS | - |
|
| 03/06 | SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent | CI |
| 11/04 | SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd. | CI |
| Sales 2022 | 1.35 4.97 112.4 | Sales 2023 | 2.88 10.62 240.25 | Capitalization | 2.56M 9.43M 213M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -7.38M -167M | Net income 2023 | -5M -18.44M -417M | EV / Sales 2022 | 11,45,812 x |
| Net cash position 2022 | 3.55M 13.08M 296M | Net cash position 2023 | 5M 18.44M 417M | EV / Sales 2023 | -8,48,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +24.53% | 44.76B | |
| +30.99% | 23.16B | |
| +24.13% | 16.02B | |
| +21.15% | 14.32B | |
| +68.67% | 13.7B | |
| -0.05% | 6.79B | |
| -13.29% | 6.47B | |
| -8.87% | 5.73B | |
| +14.00% | 5.65B |
- Stock Market
- Equities
- SPRC Stock
- TRPX Stock
